Sectoral Asset Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-2,300
| Closed | -$344K | – | 85 |
|
|
2026
Q1 | $344K | Sell |
2,300
-375
| -14% | -$49.8K | 0.28% | 66 |
|
|
2025
Q4 | $379K | Sell |
2,675
-285
| -10% | -$41.3K | 0.3% | 62 |
|
|
2025
Q3 | $416K | Hold |
2,960
| – | – | 0.26% | 70 |
|
|
2025
Q2 | $372K | Buy |
2,960
+55
| +2% | +$6.31K | 0.25% | 75 |
|
|
2025
Q1 | $321K | Sell |
2,905
-8,895
| -75% | -$1.13M | 0.25% | 61 |
|
|
2024
Q4 | $1.61M | Sell |
11,800
-715
| -6% | -$88.4K | 1.08% | 25 |
|
|
2024
Q3 | $1.44M | Buy |
12,515
+8,580
| +218% | +$1.18M | 0.85% | 37 |
|
|
2024
Q2 | $542K | Sell |
3,935
-260
| -6% | -$35.7K | 0.22% | 63 |
|
|
2024
Q1 | $579K | Sell |
4,195
-250
| -6% | -$34.1K | 0.23% | 65 |
|
|
2023
Q4 | $586K | Buy |
4,445
+410
| +10% | +$47.2K | 0.25% | 70 |
|
|
2023
Q3 | $454K | Buy |
4,035
+575
| +17% | +$60.5K | 0.09% | 108 |
|
|
2023
Q2 | $326K | Buy |
3,460
+660
| +24% | +$64.5K | 0.05% | 112 |
|
|
2023
Q1 | $283K | Hold |
2,800
| – | – | 0.05% | 110 |
|
|
2022
Q4 | $334K | Sell |
2,800
-250
| -8% | -$29.3K | 0.06% | 110 |
|
|
2022
Q3 | $324K | Hold |
3,050
| – | – | 0.06% | 97 |
|
|
2022
Q2 | $297K | Buy |
+3,050
| New | +$281K | 0.06% | 101 |
|
|
2020
Q3 | – | Sell |
-14,100
| Closed | -$1.72M | – | 148 |
|
|
2020
Q2 | $1.72M | Buy |
+14,100
| New | +$1.56M | 0.16% | 83 |
|
|
2018
Q4 | – | Sell |
-6,803
| Closed | -$836K | – | 124 |
|
|
2018
Q3 | $836K | Buy |
+6,803
| New | +$772K | 0.09% | 74 |
|
|
2018
Q2 | – | Sell |
-111,402
| Closed | -$9.24M | – | 72 |
|
|
2018
Q1 | $9.24M | Sell |
111,402
-30,900
| -22% | -$2.61M | 1.01% | 38 |
|
|
2017
Q4 | $11M | Sell |
142,302
-90,300
| -39% | -$6.16M | 1.38% | 28 |
|
|
2017
Q3 | $14.3M | Sell |
232,602
-6,105
| -3% | -$322K | 1.84% | 28 |
|
|
2017
Q2 | $11M | Sell |
238,707
-612,312
| -72% | -$29.7M | 1.2% | 30 |
|
|
2017
Q1 | $36.8M | Buy |
851,019
+102,031
| +14% | +$4.37M | 4.3% | 4 |
|
|
2016
Q4 | $29M | Sell |
748,988
-53,991
| -7% | -$2.44M | 3.21% | 12 |
|
|
2016
Q3 | $40.7M | Sell |
802,979
-209,227
| -21% | -$10.4M | 3.99% | 7 |
|
|
2016
Q2 | $46M | Sell |
1,012,206
-637,757
| -39% | -$29.4M | 4.75% | 1 |
|
|
2016
Q1 | $65.3M | Buy |
1,649,963
+1,233,283
| +296% | +$48.9M | 3.16% | 11 |
|
|
2015
Q4 | $23.6M | Buy |
+416,680
| New | +$21.2M | 1.01% | 29 |
|
Other funds holding NBIX
Sectoral Asset Management's NBIX Position: Q2 2026 in Review
Sectoral Asset Management sold out of Neurocrine Biosciences (NBIX) in Q2 2026, closing a stake of 2,300 shares — an estimated $344K sold.
Sectoral Asset Management first reported a position in NBIX in Q4 2015 and held it in 28 quarters. The position peaked at $65.3M in Q1 2016. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.
- Sectoral Asset Management reported no remaining Neurocrine Biosciences position as of Q2 2026 after selling out during the quarter.
- Sectoral Asset Management sold 2,300 Neurocrine Biosciences shares in Q2 2026, an estimated $344K.
- Sectoral Asset Management first reported a position in Neurocrine Biosciences in Q4 2015 and held it in 28 quarters.
- Sectoral Asset Management's Neurocrine Biosciences position peaked at $65.3M in Q1 2016.
- 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.
Based on Sectoral Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.